Table 4.
Relevant original articles
| Author | Study design | Included | Patient population | Diagnostic test(s) | Diagnostic evaluation | Findings |
|---|---|---|---|---|---|---|
| PET/CT Recommended | ||||||
| Gulec et al. [21] | Retrospective | 49 patients | MM patients 46 stage III/IV 3 stage II (high risk) |
FDG-PET/CT vs. CT plus brain MRI | Treatment change in 49 % | FDG-PET/CT better than CT plus brain MRI for determining extent of disease |
| Bronstein et al. [22] | Prospective | 32 patients | MM patients Clinically evident III Oligometastatic IV |
FDG-PET/CT | Treatment change in 12 % | FDG-PET/CT of use preoperatively in surgically treatable metastatic melanoma |
| Schule et al. [11] | Retrospective | 52 patients in primary staging group | MM patients stages III-IV | FDG-PET/CT vs. CT alone | Treatment change in 59 % | FDG-PET/CT better than CT alone for primary staging |
| PET/CT not recommended | ||||||
| Wagner et al. [24] | Retrospective | 46 patients | MM patients with positive SLNB | PET/CT | Treatment change in 0 % | PET/CT provides no benefit for this patient group |
| Scheier et al. [18] | Retrospective | 46 patients | MM patients with positive SNLB | PET/CT | Treatment change in 7 % | PET/CT not recommended for asymptomatic MM patients with positive SLNB micrometastasis |
MM malignant melanoma, SNLB sentinel lymph node biopsy